Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DRMA - Dermata Therapeutics, Inc.

IEX Last Trade
1.28
0.010   0.781%

Share volume: 474
Last Updated: Fri 27 Dec 2024 08:24:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$1.27
0.01
0.79%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
10.26%
1 Month
23.29%
3 Months
-13.06%
6 Months
-41.79%
1 Year
-84.41%
2 Year
-55.67%
Key data
Stock price
$1.28
P/E Ratio 
0.00
DAY RANGE
$1.27 - $1.33
EPS 
$0.00
52 WEEK RANGE
$0.62 - $13.35
52 WEEK CHANGE
-$85.18
MARKET CAP 
2.290 M
YIELD 
N/A
SHARES OUTSTANDING 
1.316 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$396,376
AVERAGE 30 VOLUME 
$682,403
Company detail
CEO: Gerry Proehl
Region: US
Website: dermatarx.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Recent news